XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 25, 2021
shares
Mar. 23, 2021
USD ($)
position
$ / shares
Feb. 28, 2021
USD ($)
shares
Feb. 18, 2021
USD ($)
$ / shares
shares
Feb. 28, 2021
USD ($)
shares
Sep. 30, 2022
USD ($)
$ / shares
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Mar. 31, 2021
shares
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
Sep. 15, 2025
Sep. 15, 2024
Sep. 15, 2023
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Loss Contingencies [Line Items]                                
Loss contingency accrual           $ 0       $ 0         $ 0  
Payments for legal settlements         $ 48,421,000                      
Common stock, par value (in dollars per share) | $ / shares           $ 0.00001       $ 0.00001         $ 0.00001  
Registration rights agreement, selling period       3 months                        
Accrued royalties under the Medytox/Allergan Settlement Agreements           $ 7,936,000       $ 7,936,000         $ 12,447,000  
Accrued litigation settlement, current           5,000,000       5,000,000         15,000,000  
Accrued litigation settlement                             20,000,000  
Consideration receivable from Daewoong           3,257,000       3,257,000         $ 5,657,000  
Inventory payments           $ 14,238,000   $ 10,916,000   $ 40,509,000 $ 24,576,000          
Daewoong Settlement Agreement                                
Loss Contingencies [Line Items]                                
Long-term purchase commitment, amount   $ 25,500,000                            
Contingent milestone payment   10,500,000                            
Daewoong Convertible Note | Convertible Debt                                
Loss Contingencies [Line Items]                                
Convertible debt   $ 40,779,000                            
Conversion price (in dollars per share) | $ / shares   $ 13.00                            
Daewoong Convertible Note | Convertible Debt | Maximum                                
Loss Contingencies [Line Items]                                
Common stock shares beneficially own percentage   0.0999                            
Forecast                                
Loss Contingencies [Line Items]                                
Share issuance agreement, percentage of share dispose per year                       75.00% 50.00% 25.00%    
Common Stock                                
Loss Contingencies [Line Items]                                
Issuance of common stock in connection with litigation settlement (in shares) | shares     6,762,652 6,762,652 6,762,652       6,762,652              
Common Stock | Daewoong Convertible Note | Convertible Debt                                
Loss Contingencies [Line Items]                                
Conversion of common shares (in shares) 3,136,869 3,136,869                            
Intellectual Property Disputes, Jeuveau                                
Loss Contingencies [Line Items]                                
Loss contingency accrual     $ 35,000,000 $ 35,000,000 $ 35,000,000                     $ 35,000,000
Settlement agreement, payment terms (in years)       2 years 2 years                      
Payments for legal settlements             $ 15,000,000 $ 15,000                
Common stock, par value (in dollars per share) | $ / shares       $ 0.00001